The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 01, 2025
Filed:
Jun. 12, 2019
Applicant:
Kyoto Biopharmaceuticals, Inc, Kyoto, JP;
Inventors:
Jerome J. Schentag, Buffalo, NY (US);
Hirofumi Nakajima, Kobe, JP;
Assignee:
KYOTO BIOPHARMACEUTICALS, INC., Kyoto, JP;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/15 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 33/22 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/38 (2006.01); A61P 31/04 (2006.01);
U.S. Cl.
CPC ...
A61K 38/15 (2013.01); A61K 9/0014 (2013.01); A61K 9/0048 (2013.01); A61K 9/06 (2013.01); A61K 33/22 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/38 (2013.01); A61P 31/04 (2018.01);
Abstract
An external or topical formulation for treatment or prevention of infections involving body surfaces using a depsipeptide antibiotic drug such as lotilibcin having improved efficacy and safety is provided. The antibacterial effect of lotilibcin tested in infectious models is substantially enhanced by addition of boric acid in a low concentration of an additive level which does not produce any pharmacological activity by itself, thereby offering a formulation for external preparations having improved safety due to a decrease in dose, dosing period, and dosing frequency.